title: Recent progress concerning CpG DNA and its use as a vaccine adjuvant.
abstract: CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding the mechanism of action of CpG ODN and provide an overview of human clinical trial results using CpG ODN to improve the vaccines for cancer, allergy and infectious disease.
authors.affiliation: Department of Clinical Oncology, Tohoku University, Japan.
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Shirota
authors.forename: Dennis M
authors.initials: DM
authors.lastname: Klinman
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D006801:Humans; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage*; D051217:Toll-Like Receptor 9 / Q000187:drug effects / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D051217:Toll-Like Receptor 9; D014612:Vaccines